Resume-aware faculty matching

Find professors who actually fit you

Upload your resume. Four AI agents analyze your background, rank the faculty who fit, inspect their recent research, and help you draft outreach — grounded in their actual work, not templates.

Free to startNo credit cardCancel anytime
Top matches Balanced preset
Dr. Sarah Chen
Stanford · Interpretability · NLP
91
Dr. Marcus Holloway
MIT · Robotics · RL
84
Dr. Aisha Okonkwo
CMU · Fairness · HCI
82
Nova · Professor Researcher · re-ranking top 20…

Craig Johnson

· Teaching Specialist

University of Minnesota · Theatre Arts and Dance

Active 1966–2024

h-index48
Citations13.3k
Papers24951 last 5y
Funding$857k
See your match with Craig Johnson — sign in to PhdFit.Sign in

Research topics

  • Genetics
  • Biology
  • Internal medicine
  • Computer Science
  • Computational biology
  • Medicine
  • Urology
  • Oncology
  • Evolutionary biology
  • Bioinformatics
  • Demography
  • Endocrinology

Selected publications

  • Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

    The Lancet · 2024 · 46 citations

    • Medicine
    • Oncology
    • Internal medicine

    BACKGROUND: Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT with postoperative radiotherapy after radical prostatectomy is unclear. METHODS: RADICALS-HD was an international randomised controlled trial to test the efficacy of ADT used in combination with postoperative radiotherapy for prostate cancer. Key eligibility criteria were indication for radiotherapy after radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to radiotherapy alone (no ADT) or radiotherapy with 6 months of ADT (short-course ADT), using monthly subcutaneous gonadotropin-releasing hormone analogue injections, daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as distant metastasis arising from prostate cancer or death from any cause. Standard survival analysis methods were used, accounting for randomisation stratification factors. The trial had 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 80% to 86% (hazard ratio [HR] 0·67). Analyses followed the intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov, NCT00541047. FINDINGS: Between Nov 22, 2007, and June 29, 2015, 1480 patients (median age 66 years [IQR 61-69]) were randomly assigned to receive no ADT (n=737) or short-course ADT (n=743) in addition to postoperative radiotherapy at 121 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 9·0 years (IQR 7·1-10·1), metastasis-free survival events were reported for 268 participants (142 in the no ADT group and 126 in the short-course ADT group; HR 0·886 [95% CI 0·688-1·140], p=0·35). 10-year metastasis-free survival was 79·2% (95% CI 75·4-82·5) in the no ADT group and 80·4% (76·6-83·6) in the short-course ADT group. Toxicity of grade 3 or higher was reported for 121 (17%) of 737 participants in the no ADT group and 100 (14%) of 743 in the short-course ADT group (p=0·15), with no treatment-related deaths. INTERPRETATION: Metastatic disease is uncommon following postoperative bed radiotherapy after radical prostatectomy. Adding 6 months of ADT to this radiotherapy did not improve metastasis-free survival compared with no ADT. These findings do not support the use of short-course ADT with postoperative radiotherapy in this patient population. FUNDING: Cancer Research UK, UK Research and Innovation (formerly Medical Research Council), and Canadian Cancer Society.

  • Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data

    Nature Genetics · 2022 · 354 citations

    • Biology
    • Genetics
  • Whole genome sequence analysis of blood lipid levels in >66,000 individuals

    Nature Communications · 2022 · 73 citations

    • Genetics
    • Biology
    • Computational biology

    Blood lipids are heritable modifiable causal factors for coronary artery disease. Despite well-described monogenic and polygenic bases of dyslipidemia, limitations remain in discovery of lipid-associated alleles using whole genome sequencing (WGS), partly due to limited sample sizes, ancestral diversity, and interpretation of clinical significance. Among 66,329 ancestrally diverse (56% non-European) participants, we associate 428M variants from deep-coverage WGS with lipid levels; ~400M variants were not assessed in prior lipids genetic analyses. We find multiple lipid-related genes strongly associated with blood lipids through analysis of common and rare coding variants. We discover several associated rare non-coding variants, largely at Mendelian lipid genes. Notably, we observe rare LDLR intronic variants associated with markedly increased LDL-C, similar to rare LDLR exonic variants. In conclusion, we conducted a systematic whole genome scan for blood lipids expanding the alleles linked to lipids for multiple ancestries and characterize a clinically-relevant rare non-coding variant model for lipids.

  • Whole-genome association analyses of sleep-disordered breathing phenotypes in the NHLBI TOPMed program

    Genome Medicine · 2021 · 34 citations

    • Genetics
    • Medicine
    • Biology

    BACKGROUND: Sleep-disordered breathing is a common disorder associated with significant morbidity. The genetic architecture of sleep-disordered breathing remains poorly understood. Through the NHLBI Trans-Omics for Precision Medicine (TOPMed) program, we performed the first whole-genome sequence analysis of sleep-disordered breathing. METHODS: The study sample was comprised of 7988 individuals of diverse ancestry. Common-variant and pathway analyses included an additional 13,257 individuals. We examined five complementary traits describing different aspects of sleep-disordered breathing: the apnea-hypopnea index, average oxyhemoglobin desaturation per event, average and minimum oxyhemoglobin saturation across the sleep episode, and the percentage of sleep with oxyhemoglobin saturation < 90%. We adjusted for age, sex, BMI, study, and family structure using MMSKAT and EMMAX mixed linear model approaches. Additional bioinformatics analyses were performed with MetaXcan, GIGSEA, and ReMap. RESULTS: ) on chromosome X with ARMCX3. Additional rare-variant associations include ARMCX3-AS1, MRPS33, and C16orf90. Novel common-variant loci were identified in the NRG1 and SLC45A2 regions, and previously associated loci in the IL18RAP and ATP2B4 regions were associated with novel phenotypes. Transcription factor binding site enrichment identified associations with genes implicated with respiratory and craniofacial traits. Additional analyses identified significantly associated pathways. CONCLUSIONS: We have identified the first gene-based rare-variant associations with objectively measured sleep-disordered breathing traits. Our results increase the understanding of the genetic architecture of sleep-disordered breathing and highlight associations in genes that modulate lung development, inflammation, respiratory rhythmogenesis, and HIF1A-mediated hypoxic response.

  • Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program

    Nature · 2021 · 2261 citations

    • Computer Science
    • Biology
    • Genetics

    . In the first 53,831 TOPMed samples, we detected more than 400 million single-nucleotide and insertion or deletion variants after alignment with the reference genome. Additional previously undescribed variants were detected through assembly of unmapped reads and customized analysis in highly variable loci. Among the more than 400 million detected variants, 97% have frequencies of less than 1% and 46% are singletons that are present in only one individual (53% among unrelated individuals). These rare variants provide insights into mutational processes and recent human evolutionary history. The extensive catalogue of genetic variation in TOPMed studies provides unique opportunities for exploring the contributions of rare and noncoding sequence variants to phenotypic variation. Furthermore, combining TOPMed haplotypes with modern imputation methods improves the power and reach of genome-wide association studies to include variants down to a frequency of approximately 0.01%.

  • De novo mutations across 1,465 diverse genomes reveal mutational insights and reductions in the Amish founder population

    Proceedings of the National Academy of Sciences · 2020 · 110 citations

    • Genetics
    • Biology
    • Evolutionary biology

    ), which suggest that variation in DNM rate is significantly shaped by nonadditive genetic effects and the environment.

Recent grants

Frequent coauthors

  • João A.C. Lima

    Johns Hopkins Medicine

    175 shared
  • David A. Bluemke

    University of Wisconsin–Madison

    144 shared
  • W. Gregory Hundley

    126 shared
  • Antoinette S. Gomes

    125 shared
  • Martin R. Prince

    124 shared
  • John Eng

    Morgan State University

    123 shared
  • J. Jeffrey Carr

    Vanderbilt University Medical Center

    123 shared
  • Nadine Kawel

    National Institute of Biomedical Imaging and Bioengineering

    123 shared

Similar researchers at University of Minnesota

  • Resume-aware match score
  • Save to shortlist
  • AI-drafted outreach

See your match with Craig Johnson

PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.

  • Free to start
  • No credit card
  • 30-second signup